Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from
Regeneron Pharmaceuticals announced that the EMA's CHMP has recommended conditional marketing authorization for linvoseltamab to treat relapsed/refractory multiple myeloma in adults. The European Commission will make a final decision soon.
February 28, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' linvoseltamab has received a positive opinion from the EMA's CHMP for treating relapsed/refractory multiple myeloma, potentially leading to conditional marketing authorization in the EU.
The CHMP's positive opinion is a significant step towards EU approval, which could enhance Regeneron's product portfolio and revenue. The final decision by the European Commission is pending, but the recommendation suggests a favorable outcome.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100